polyneuropathy

(redirected from Familial amyloid polyneuropathy)
Also found in: Medical, Wikipedia.
Related to Familial amyloid polyneuropathy: Amyloid angiopathy
Translations

pol·y·neu·rop·a·thy

n. polineuropatía, enfermedad que afecta varios nervios a la vez.

polyneuropathy

n polineuropatía
References in periodicals archive ?
Psychological aspects of pre-symptomatic testing for Machado-Joseph disease and familial amyloid polyneuropathy type I.
This study will enable to know the reasons why subjects at-risk for Familial Amyloid Polyneuropathy (FAP), Huntington's Disease (HD), and Machado-Joseph Disease (MJD) want to perform the PST and compare the results with the motivations of the subjects atrisk for Hereditary Hemochromatosis (HH) which also wish to carry the presymptomatic testing (PST).
announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP).
Familial amyloid polyneuropathy (FAP) type IV (FINNISH) is a very rare life-threatening disorder and reported only in a few countries.
Global Markets Direct's, 'Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, H2 2015', provides an overview of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)'s therapeutic pipeline.
Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients.
has earned a $15 million milestone payment from GSK related to advancing the Phase II/III study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Thursday the receipt of USD18m milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
M2 PHARMA-July 16, 2014-Isis Pharmaceuticals receives USD1m milestone for advancing ISIS-TTR Rx for treatment of familial amyloid polyneuropathy
This report provides information on the therapeutic development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease), complete with latest updates, and special features on late-stage and discontinued projects.
Late-onset familial amyloid polyneuropathy type I (Transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan.
Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation.
Full browser ?